First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor - Top-Institutions - MDSpire

First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor

  • By

  • Juan Bu

  • Yeledan Mahan

  • Reziwanguli Yuemaier

  • Xiaoling Zhang

  • Ling Zhou

  • May 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Sarcoma

  • #2

    Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Sarcoma

  • #3

    Moores Cancer Center at UC San Diego Health
    Moores Cancer Center at UC San Diego Health

    La Jolla, California

    Key Differentiators

    • Oncology
    • Gastrointestinal Cancer

  • #4

    University of California, San Diego School of Medicine
    University of California, San Diego School of Medicine

    La Jolla, California

    Key Differentiators

    • Oncology
    • Medical Education

  • #5

    National Cancer Center
    National Cancer Center

    Tokyo, Japan

    Key Differentiators

    • Oncology
    • Cancer Research

Original Source(s)

First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor

  • by Juan Bu, Yeledan Mahan, Reziwanguli Yuemaier, Xiaoling Zhang, Ling Zhou

  • May 20, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort